2017
Bone metastasis-related signaling pathways in breast cancers stratified by estrogen receptor status
Hayashi N, Iwamoto T, Qi Y, Niikura N, Santarpia L, Yamauchi H, Nakamura S, Hortobagyi GN, Pusztai L, Symmans WF, Ueno NT. Bone metastasis-related signaling pathways in breast cancers stratified by estrogen receptor status. Journal Of Cancer 2017, 8: 1045-1052. PMID: 28529618, PMCID: PMC5436258, DOI: 10.7150/jca.13690.Peer-Reviewed Original ResearchER-negative breast cancerEstrogen receptor statusBone metastasesER statusBreast cancerReceptor statusHuman epidermal growth factor receptor 2Breast cancer bone metastasisEpidermal growth factor receptor 2Cox proportional hazards modelNon-bone metastasisGrowth factor receptor 2Cancer bone metastasisProportional hazards modelBreast cancer specimensInvasive breast cancer specimensFactor receptor 2Negative cohortCancer specimensHazards modelReceptor 2BCBMMetastasisCancerCohort
2012
12O_PR Independent Blinded Validation of the Genomic Index of Sensitivity to Endocrine Therapy (Set)
Karn T, Hatzis C, Symmans W, Pusztai L, Ruckhäberle E, Schmidt M, Müller V, Holtrich U, Rody A, Kaufmann M. 12O_PR Independent Blinded Validation of the Genomic Index of Sensitivity to Endocrine Therapy (Set). Annals Of Oncology 2012, 23: ii18. DOI: 10.1016/s0923-7534(19)65684-x.Peer-Reviewed Original ResearchEndocrine therapyPositive patientsPrognostic valueTumor sizeER-positive primary breast cancerPositive primary breast cancerAdjuvant endocrine therapyNegative PgR statusNode-negative cohortPure prognostic valueNode-negative patientsStepwise Cox regressionER-positive patientsPrimary breast cancerBest independent predictorPgR statusAdjuvant treatmentRetrospective cohortIndependent predictorsLymph nodesNegative cohortSurvival benefitCox regressionClinical associationsHER2 status